NCT03259399

A Pharmacogenomics Study of Safety and Efficacy of Enalapril or Enalapril-Folic Acid Therapy in Hypertensive Patients.

A Study of Genetic Variants Associated With Enalapril-Induced Adverse Drug Reaction and Impact of Pharmacogenomics on First Stroke in Hypertensive Patients Taking Enalapril or Enalapril-Folic Acid Therapy.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 2,200 (estimated)
• Sponsor: Cui Yimin · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Dry cough is the most common adverse reaction of angiotensin converting enzyme, including enalapril, in Chinese population. Clinical observations suggest that the incidence of ACEI-induced dry cough is different between Chinese and other racial groups, however, there is still lack of research data in Chinese. Stroke is the second leading cause of death in the world and leading cause of death in China. Except the known risk factor such as hypertension, high homocysteine level, folic acid deficiency, the impact of genetics should not be ignored. In this study, we will investigate whether there are specific genotypes which may predict the incidence of (1)enalapril-induced dry cough in Chinese and (2)first stroke in hypertensive patients taking enalapril or enalapril-folic acid therapy, so as to provide a basis for developing guidelines on precision medication in enalapril therapy apply to Chinese population.

Conditions

• Enalapril Adverse Reaction
• Pharmacogenomics
• Stroke

Interventions

Type	Name	Description
GENETIC	detection of genotype	detection of genotype by next generation sequencing

Timeline

• Start date: 2017-08-16
• Primary completion: 2020-06-01
• Completion: 2020-06-01
• First posted: 2017-08-23
• Last updated: 2019-08-28

Locations

1 site across 1 country: China